Multiple Myeloma Clinical Trial

A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Summary

The purpose of the study is to compare CC-92480 (BMS-986348) with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:

Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or
M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,
For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio .
Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).
Participant must have received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody.
Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
Participant must have documented disease progression during or after their last antimyeloma regimen.

Exclusion Criteria:

Participant who has had prior treatment with CC-92480 or carfilzomib.
Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.

Additional protocol-defined criteria apply.

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

525

Study ID:

NCT05552976

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 68 Locations for this study

See Locations Near You

Kaiser Permanente - Irvine
Irvine California, 92618, United States More Info
Ashraf Aziz, Site 0190
Contact
800-398-3996
Innovative Clinical Research Institute
Whittier California, 90603, United States More Info
Amitabha Mazumder, Site 0005
Contact
562-693-4477
Augusta University
Augusta Georgia, 30912, United States More Info
Amany Keruakous, Site 0188
Contact
706-721-2505
Novant Health Cancer Institute - Elizabeth
Charlotte North Carolina, 28204, United States
Riverside Methodist Hospital
Columbus Ohio, 43214, United States More Info
Yvonne Efebera, Site 0172
Contact
216-965-8569
Charleston Oncology, P.A.
Charleston South Carolina, 29414, United States More Info
George Geils, Site 0173
Contact
843-577-6957
Houston Methodist Hospital
Houston Texas, 77030, United States More Info
Carrie Yuen, Site 0044
Contact
832-571-7244
Baylor Scott & White Medical Center - Temple
Temple Texas, 76508, United States More Info
Rex Garland, Site 0195
Contact
254-724-5918
Northwest Medical Specialties - Gig Harbor
Tacoma Washington, 98405, United States More Info
Francis Senecal, Site 0006
Contact
253-428-8700
Local Institution - 0182
Rosario Santa Fe, S2000, Argentina More Info
Site 0182
Contact
Local Institution - 0150
Buenos Aires , 1431, Argentina More Info
Site 0150
Contact
Local Institution - 0079
Ciudad Autónoma de Buenos Aires , C1199, Argentina More Info
Site 0079
Contact
Local Institution - 0151
Córdoba , 5000, Argentina More Info
Site 0151
Contact
Local Institution - 0077
Camperdown New South Wales, 2050, Australia More Info
Site 0077
Contact
Local Institution - 0041
Brisbane Queensland, 4029, Australia More Info
Site 0041
Contact
Local Institution - 0131
Bendigo Victoria, 3550, Australia More Info
Site 0131
Contact
Local Institution - 0160
Gosford , 2250, Australia More Info
Site 0160
Contact
Local Institution - 0121
Salvador Bahia, 41253, Brazil More Info
Site 0121
Contact
Local Institution - 0076
Porto Alegre Rio Grande Do Sul, 90470, Brazil More Info
Site 0076
Contact
Local Institution - 0085
Sao Paulo São Paulo, 01509, Brazil More Info
Site 0085
Contact
Local Institution - 0075
Rio de Janeiro , 22793, Brazil More Info
Site 0075
Contact
Local Institution - 0073
São Paulo , 04537, Brazil More Info
Site 0073
Contact
Local Institution - 0183
Halifax Nova Scotia, B3H 2, Canada More Info
Site 0183
Contact
Local Institution - 0184
Toronto Ontario, M5G 2, Canada More Info
Site 0184
Contact
Local Institution - 0186
Montreal Quebec, H3T 1, Canada More Info
Site 0186
Contact
Local Institution - 0057
Beijing Beijing, 10002, China More Info
Site 0057
Contact
Local Institution - 0061
Beijing Beijing, 10002, China More Info
Site 0061
Contact
Local Institution - 0056
Beijing Beijing, 10073, China More Info
Site 0056
Contact
Local Institution - 0123
Fuzhou Fujian, 35000, China More Info
Site 0123
Contact
Local Institution - 0138
Guangzhou Guangdong, 51006, China More Info
Site 0138
Contact
Local Institution - 0051
Zhengzhou Henan, 45000, China More Info
Site 0051
Contact
Local Institution - 0071
Changsha Hunan, 41001, China More Info
Site 0071
Contact
Local Institution - 0103
Changsha Hunan, 41001, China More Info
Site 0103
Contact
Local Institution - 0111
Nantong Jiangsu, 22600, China More Info
Site 0111
Contact
Local Institution - 0104
Suzhou Jiangsu, 21500, China More Info
Site 0104
Contact
Local Institution - 0069
Wuxi Jiangsu, 21402, China More Info
Site 0069
Contact
Local Institution - 0052
Changchun Jilin, 13002, China More Info
Site 0052
Contact
Local Institution - 0096
Shenyang Liaoning, 11000, China More Info
Site 0096
Contact
Local Institution - 0176
Shenyang Liaoning, 11000, China More Info
Site 0176
Contact
Local Institution - 0060
Xi'an Shaanxi, 71012, China More Info
Site 0060
Contact
Local Institution - 0072
Jinan Shandong, 25001, China More Info
Site 0072
Contact
Local Institution - 0118
Shanghai Shanghai, 0, China More Info
Site 0118
Contact
Local Institution - 0091
Tianjin Tianjin, 30006, China More Info
Site 0091
Contact
Local Institution - 0058
Kunming Yunnan, 65010, China More Info
Site 0058
Contact
Local Institution - 0050
Hangzhou Zhejiang, 31000, China More Info
Site 0050
Contact
Local Institution - 0059
Taiyuan , 03003, China More Info
Site 0059
Contact
Local Institution - 0153
Medellin Antioquia, 05034, Colombia More Info
Site 0153
Contact
Local Institution - 0156
Valledupar Cesar, 20000, Colombia More Info
Site 0156
Contact
Local Institution - 0154
Bogota Cundinamarca, 11115, Colombia More Info
Site 0154
Contact
Local Institution - 0155
Cali Valle Del Cauca, 0, Colombia More Info
Site 0155
Contact
Local Institution - 0048
Copenhagen Hovedstaden, 2100, Denmark
Local Institution - 0030
Leipzig Saxony, 04103, Germany More Info
Site 0030
Contact
Local Institution - 0178
Hong Kong , 0, Hong Kong More Info
Site 0178
Contact
Local Institution - 0170
New Delhi Delhi, 11008, India More Info
Site 0170
Contact
Local Institution - 0167
Gurgaon Haryana, 12200, India More Info
Site 0167
Contact
Local Institution - 0161
Bengaluru Karnataka, 56002, India More Info
Site 0161
Contact
Local Institution - 0168
Mumbai Maharashtra, 40001, India More Info
Site 0168
Contact
Local Institution - 0171
Thane Maharashtra, 40060, India More Info
Site 0171
Contact
Local Institution - 0174
Chennai Tamil Nadu, 60003, India More Info
Site 0174
Contact
Local Institution - 0165
Hyderabad Telangana, 50003, India More Info
Site 0165
Contact
Local Institution - 0164
Hyderabad Telangana, 50008, India More Info
Site 0164
Contact
Local Institution - 0163
Kolkata West Bengal, 70001, India More Info
Site 0163
Contact
Local Institution - 0142
Rozzano Milano, 20089, Italy More Info
Site 0142
Contact
Local Institution - 0189
Bologna , 40138, Italy More Info
Site 0189
Contact
Local Institution - 0147
Lecce , 73100, Italy More Info
Site 0147
Contact
Local Institution - 0194
Enschede , 7512 , Netherlands
Local Institution - 0112
Stavanger Rogaland, 4011, Norway More Info
Site 0112
Contact
Local Institution - 0158
Singapore Central Singapore, 11907, Singapore More Info
Site 0158
Contact
Local Institution - 0159
Singapore Central Singapore, 16960, Singapore More Info
Site 0159
Contact
Local Institution - 0192
San Cristobal de La laguna Santa Cruz De Tenerife, 38320, Spain More Info
Site 0192
Contact
Local Institution - 0177
Kaohsiung City Kaohsiung, 83301, Taiwan More Info
Site 0177
Contact
Local Institution - 0012
Kaohsiung , 82445, Taiwan More Info
Site 0012
Contact
Local Institution - 0149
Taipei , 11217, Taiwan
Local Institution - 0162
Taipei , 11217, Taiwan More Info
Site 0162
Contact

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

525

Study ID:

NCT05552976

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.